PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Symptom | C0525041|cognitive symptom |
| Sentences | 9 |
| PubMedID- 25403863 | This article summarizes the phenomenology, prevalence, assessment, and treatment of negative and cognitive symptoms in patients with schizophrenia, including pharmacologic and nonpharmacologic management strategies that can be used in clinical care now, as well as pharmacologic approaches that are being tested. |
| PubMedID- 22847727 | The present case-control study examined socio-demographic and substance use disorder (sud) variables as well as psychiatric, extrapyramidal, and cognitive symptoms as predictors of community functioning in schizophrenia patients with (dd patients; n=31) and without comorbid suds (scz patients; n=31), and non-psychosis substance abusers (sud patients; n=39). |
| PubMedID- 26086615 | The α7 nachr is therefore considered a promising drug target for the treatment of cognitive symptoms in patients with schizophrenia or alzheimer’s disease, and this has led to an intensive drug development effort to produce α7 nachr selective agonists and positive allosteric modulators (reviewed in ). |
| PubMedID- 23842600 | schizophrenia is typically associated with higher-level cognitive symptoms, such as disorganized thoughts, delusions, and hallucinations. |
| PubMedID- 24324444 | Nmdar antagonists also worsen positive, negative, and cognitive symptoms in patients with schizophrenia (7, 8). |
| PubMedID- 21423454 | In summary, given the negligible efficacy of haloperidol and risperidone, the contradictory data with donepezil to treat cognitive symptoms associated with schizophrenia in the clinic (harvey and keefe, 2001; keefe et al., 2007a), and the promising preliminary pro-cognitive effects of modafinil in certain subsets of schizophrenic patients (morein-zamir et al., 2007), the sub-chronic pcp–nor abstinence paradigm may represent an attractive option for the identification of potential novel treatments. |
| PubMedID- 20226539 | Since oral administration of d-alanine, an agonist that binds to the glycine site of n-methyl-d-aspartate (nmda) receptors, improves the positive and cognitive symptoms of patients with schizophrenia, measurement of endogenous plasma alanine levels could serve as a clinical marker for schizophrenia severity and improvement. |
| PubMedID- 20812877 | Currently, no effective treatment for the cognitive symptoms in schizophrenia exists. |
| PubMedID- 23630632 | Secondly, treatment with d-serine is beneficial for reducing positive, negative and cognitive symptoms in patients with schizophrenia , . |
Page: 1